Bharat Biotech s Typbar TCV the world s first clinically proven Typhoid Conjugate Vaccine against typhoid fever has received prequalification from World Health Organisation (WHO). Typbar TCV is the first typhoid vaccine clinically proven to be administered to children from 6 months of age to adults and confers long-term protection against typhoid fever. Oxford University conducted a human challenge study with Typbar TCV at 25 g / dose where the subjects were challenged with live S. Typhi proving a protective efficacy of 87% against typhoid fever. WHO-SAGE recommended the use of typhoid conjugate vaccines for use in infants between